Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Keratosis, Actinic 5Skin Diseases 1Precancerous Conditions 1Keratosis 1Carcinoma, Basal Cell 1

Interventions

Aminolevulinic Acid 2tirbanibulin 1ruxolitinib 1human papillomavirus vaccine, L1 type 16, 18 1Watchful Waiting 1Transurethral Resection of Prostate 1Toremifene 1Robotic Surgical Procedures 1Pregnancy Tests 1Hysterectomy 1Human Papillomavirus DNA Tests 1Excipients 1Colposcopy 1Celecoxib 1CPI-0610 1Blood Specimen Collection 1Biopsy 1BF-200 ALA 1Acetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Precancerous Conditions × BF-200 ALA × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡